November 18, 2025 — Leads & Copy — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) announced the publication of new research in Nature Communications, validating its approach to treating Duchenne muscular dystrophy and other diseases. The research, conducted by a team at the Ottawa Hospital Research Institute (OHRI), reveals that Duchenne begins during fetal development as a stem cell disease characterized by intrinsic muscle stem cell dysfunction.
The paper, authored by OHRI researchers including Satellos co-founder and Chief Discovery Officer Dr. Michael Rudnicki, showed that in the absence of dystrophin, muscle stem cells lose polarity and produce fewer myogenic progenitors, leading to fewer and smaller muscle fibers. These changes occur during fetal muscle development before inflammation or tissue degeneration appears.
Researchers demonstrated that muscle stem cells lacking dystrophin could be induced to achieve polarity, generate new progenitor cells, and form normal amounts of muscle by blocking the activity of the protein AAK1. These findings support the potential of an AAK1 inhibitor, such as SAT-3247, to restore muscle regeneration in Duchenne.
Dr. Rudnicki, also an OHRI senior scientist and director of the Sprott Centre for Stem Cell Research, stated that the findings make it clear that Duchenne begins as a failure of muscle stem cells to build and maintain muscle. He added that modulating AAK1 provides a means to regulate polarity, normalize stem cell function, and enhance muscle formation in dystrophic models, pointing to regenerative treatment strategies.
Satellos co-founder and CEO Frank Gleeson said the findings further validate the conviction that correcting stem-cell dysfunction is essential to changing the trajectory of Duchenne. He congratulated Dr. Rudnicki and his OHRI colleagues for uncovering and confirming muscle biology that may open doors to more effective intervention.
SAT-3247, a proprietary, oral, small molecule drug being developed by Satellos, is a novel treatment to regenerate skeletal muscle lost in Duchenne muscular dystrophy and other degenerative or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD, independent of dystrophin and regardless of exon mutation status.
The Ottawa Hospital Research Institute, the research arm of The Ottawa Hospital, is affiliated with the University of Ottawa and supported by The Ottawa Hospital Foundation. With over 2,200 scientists, clinician investigators, trainees, and staff, it focuses on translating discoveries and knowledge into better health, spanning more than a hundred different diseases, conditions, and specialties.
Satellos Bioscience Inc. is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, which Satellos identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. Satellos also leverages its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities.
Frank Gleeson, Satellos co-founder and CEO
Source: Satellos Bioscience Inc.
